Fusion Biopsy Market

At a compound annual growth rate (CAGR) of 7.1%, the fusion biopsy market is projected to grow from its estimated USD 0.65 billion in 2024 to USD 0.91 billion by 2029. The market for fusion biopsy is growing rapidly due to the rising incidence of prostate cancer and the rapid aging of the global population. Growing awareness of early cancer diagnosis and advancements in imaging and diagnostic technologies have led to an increase in the usage of fusion biopsy techniques. Supporting factors like improved healthcare infrastructure, easier access to reimbursement policies, and governmental and private sector expenditures are driving the market's growth.

The fusion biopsy market is highly consolidated, with top companies holding significant market shares. The top three players in this market include Koninklijke Philips N.V. (Netherlands), GE HealthCare (US), and KOELIS (France). Players in this market are focusing on adopting organic and inorganic growth strategies such as product launches and collaborations to increase their fusion biopsy portfolio, cater to customer needs, increase their profitability and expand their presence in the global fusion biopsy market.

To know about the assumptions considered for the study download the pdf brochure

Koninklijke Philips N.V. (Netherlands)

Philips has dominated the fusion biopsy market in 2023, mostly as a result of its innovative solutions and state-of-the-art imaging technology, such the well-known UroNav system. UroNav's renowned accuracy and effectiveness in detecting prostate cancer make it one of the best MRI-ultrasound fusion biopsy systems on the market. Additionally, this company is committed to developing its R&D capabilities. For example, combined five different R&D sites into a single R&D hub in Bangalore, India, in 2023, which could house over 5,000 workers. The company is maintaining a dominant position in the fusion biopsy industry because to these advancements and its robust product line.

GE HealthCare (US)

GE HealthCare is the second-largest player in the fusion biopsy market as of 2023. The company earns revenue from a wide variety of products, including medical devices, consumables, services, and digital solutions. GE’s advancements in MRI and ultrasound technology improve image quality and integration, making fusion biopsy procedures more effective. Moreover, GE HealthCare’s focus on AI and digital solutions aids in advancing image-guided biopsy techniques, making it possible to perform more accurate and efficient diagnostics. GE HealthCare’s role in the fusion biopsy market is substantial due to its leadership in imaging technology and healthcare solutions.

KOELIS (France)

KOELIS, which focuses on advanced imaging and targeted technologies for prostate cancer diagnostics, is the third-largest player in the fusion biopsy market in 2023. It is a significant rival in this field because of its state-of-the-art fusion biopsy systems, such the Trinity system, which increase accuracy in MRI-ultrasound fusion-guided biopsies. Strategic alliances, like the one with DeepHealth, are an important aspect of the company's approach. The goal of this collaboration was to enhance the precision and effectiveness of prostate cancer diagnosis by combining KOELIS's imaging technology with DeepHealth's AI-driven solutions. Through such collaborations, KOELIS enhances its technological offerings, expands its reach, and strengthens its position within the fusion biopsy market.

Related Reports:

Fusion Biopsy Market by Route Type (Transrectal, Transperineal), Product (Equipment, Consumables), Application (Prostate Cancer), End User (Hospitals), and Region - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]